Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem cell transplantation

Abstract

We evaluated the response and toxicity of rituximab in the setting of progressive intermediate grade non-Hodgkin’s lymphoma (NHL) after autologous peripheral stem cell transplantation (PSCT). Seven patients with a median age of 59 years (45–62), ECOG performance status 0–1, and CD20-positive diffuse large cell lymphoma with progression after PSCT were treated. All patients initially received 4-weekly infusions of rituximab (375 mg/m²). The maximum response was three CR and four PR. Median progression-free survival was 197 days (range 60–282). With a median follow-up of 204 (115–299) days, the patients’ disease status is classified as two CR, one PR, and four PD. Four of five patients with ECOG performance status of 1 prior to treatment showed improvement to status 0 after treatment with rituximab. While follow-up is short, these results suggest that rituximab has significant activity in intermediate-grade non-Hodgkin’s lymphoma that has relapsed after PSCT.